Right Heart Protective Ventilation Strategies
June 1, 2015 11 minutes read
Richard Kallet, MS, RRT, FAARC, FCCM
Director of Quality Assurance, Respiratory Care Services, San Francisco General Hospital
Mr. Kallet reports no financial relationships relevant to this field of study.
The pulmonary vascular system must conduct the entire cardiac output through the lungs. Unlike other organs, the lungs possess a massive capillary system imbedded into a considerably less dense, air-tissue structure. As such, the pulmonary vasculature functions as a low-resistance, high-capacitance system reflected in the design of the right ventricle (RV): a thin-walled muscular chamber. Relatively small changes in pulmonary arterial pressure (PAP) are associated with large volume changes.
Given these limitations, RV performance is vulnerable to the effects of both pulmonary disease and positive pressure ventilation. A hallmark of acute respiratory distress syndrome (ARDS) is pronounced pulmonary arterial and capillary endothelial injury resulting in arterial and microvascular thrombosis; vascular constriction from the effects of hypoxemia; hypercapnia and acidosis; vascular compression from pulmonary edema; and alveolar hyperinflation caused by mechanical ventilation.1-4 Over time, these acute changes evolve into a chronic phase characterized by vascular smooth muscle hypertrophy, fibrosis, and capillary obliteration.5
Pulmonary arterial hypertension (PAH) is defined as a mean PAP ≥ 25 mmHg when the corresponding pulmonary arterial occlusion pressure (PAOP) is < 15 mmHg.6 PAH can lead to RV dysfunction and acute cor pulmonale (ACP), characterized by severe RV dilation and paradoxical septal motion during systole, eventually causing left ventricular failure and progressive systemic hypotension if not reversed.7 It should be noted, however, that moderate RV dilation itself is not indicative of dysfunction; when combined with interventricular dyskinesia, it represents RV overload.8 The incidence of ACP in patients with ARDS is 22-25% and 50% in those with severe ARDS. 8-11 Patent foramen ovale with right-to-left intracardiac shunting occurs in approximately 16-19% of patients with ARDS and may further complicate management of hypoxemia.8,9
Prior to the advent of lung protective ventilation (LPV) strategies, there was a strong association between severity of PAH and mortality in ARDS. Mortality rates of 88% were reported in those with pulmonary vascular obstruction on angiography vs 50% in those with elevated pulmonary vascular resistance (PVR) but no vascular obstruction.12 Patients whose right atrial pressure exceeded PAOP also had a mortality risk that was five-fold greater.13 A large study of hemodynamic profiles in ARDS found that an elevated right over left ventricular stroke work index ratio was also highly predictive for mortality.14
Even in the era of LPV, increased pulmonary vascular resistance remains a common finding in ARDS, although the exact relationship between ACP and mortality in ARDS has become less clear. Some studies have reported a mortality rate of 32% in ARDS, regardless of the presence or absence of ACP.8 Others argue that ACP does not appear to influence mortality in ARDS when not aggravated by mechanical ventilation strategies (e.g., high positive end-expiratory pressure [PEEP], high plateau pressure [Pplat]).15 In contrast, Boissier et al found that in moderate-to-severe ARDS managed with LPV, the development of ACP carries a significantly higher hospital mortality (67% vs 49%).16 Likewise, a post-hoc analysis of the ARDS Network FACTT study found that patients with an elevated transpulmonary gradient (mean PAP-PAOP > 12 mmHg) also had a substantially higher mortality rate (30% vs 19%).17
The concepts of LPV and right heart protective ventilation strategies have been considered together. However, the latter approach imposes substantially stricter limitations on ventilator settings that render its application in patients with severe ARDS problematic, particularly in those with chest wall restriction. Carefully gathered observational data have reported that elevated Pplat is associated with both an increased incidence of ACP and mortality in ARDS. In particular, there appears to be an additive effect between elevated Pplat, ACP, and mortality risk. For example, those with a Pplat of 27-35 cm H2O and ACP had a three-fold higher mortality than those with normal RV function.15 Therefore, targeting a Pplat for LPV should consider current right heart function. The suggested goal is a Pplat < 26 cm H2O.15 Furthermore, a right heart protective approach targets a driving pressure (Pplat-PEEP) < 17 cm H2O; in light of more recent evidence, some have even argued for a driving pressure target of < 15 cmH2O.18,19 As a result, PEEP would be limited to < 12 cm H2O (at least in the presence of ACP). Proponents of this approach also advocate strongly for routine echocardiographic evaluation of patients early in the course of severe ARDS.
Also in contrast to traditional LPV approaches, even moderate hypercapnia should be avoided as both respiratory and metabolic acidosis increase pulmonary vascular resistance, and hypercapnia itself can exacerbate hypoxic pulmonary vasoconstriction.20-22 The recommended target is a PaCO2 < 60 mmHg, as values greater than this are associated with a nearly four-fold increased risk for ACP.10,18 Strategies to avoid hypercapnia can include upward titration of respiratory rate and removal of additional apparatus dead space (e.g., heat-moisture exchangers). These strategies, however, can in turn become problematic, as high respiratory rates during LPV are associated with intrinsic PEEP that can impair RV function and CO2 excretion when inspiratory time is not shortened.23 In turn, if inspiratory time is abbreviated too much in an effort to reduce dynamic gas trapping (e.g., to pediatric levels of < 0.7 seconds), this can also exacerbate hypercapnia by magnifying airway dead space.
What arterial pH should be targeted to protect RV function in severe ARDS is unclear. In an animal model of acute lung injury, severe respiratory acidosis (pH = 7.13) increased mean PAP and PVR by 65% and 80%, respectively. 26 These values returned towards normal when extracorporeal CO2 removal returned pH to 7.36. In a lactic acidosis model, mean PAP rises significantly at pH < 7.20 and approaches 50 mmHg at a pH of 7.10.20 Thus, in severe ARDS, adjusting supportive therapy to achieve an initial pH target > 7.20 (and ideally > 7.30) appears to be reasonable.
Despite LPV, even a moderate PEEP level (13 cm H2O) impairs RV function.27 Acute respiratory acidosis exacerbates this, where deterioration in RV function occurs at even lower levels of PEEP (11 cm H2O).22 However, the impact of PEEP on RV function may depend more on whether its application results in lung recruitment vs overdistension. Both atelectasis and alveolar overdistension are significant causes of RV afterload. A recent study suggests that when PEEP primarily causes alveolar recruitment, the negative impact on RV function is minimized.22 Other investigators have reported that moderate PEEP levels (14 cm H2O) with LPV and recruitment maneuvers did not negatively impact RV function in postoperative cardiac surgery patients whose chest compliance was similar to ARDS (35-40 mL/cm H2O).28 Recruitment maneuvers reduce atelectasis so that increases in functional (aerated) lung tissue may help reduce alveolar overdistension. Nonetheless, cardiac surgery patients typically do not exhibit pronounced pulmonary arterial and microvascular obstruction characteristic of ARDS. Generalizing these findings to ARDS requires caution.
Eighty percent of hypoxic pulmonary vasoconstriction occurs when local alveolar PO2 falls below 50-70 mmHg (the remaining 20% is attributable to abnormally low mixed venous PO2).29,30 Its impact on RV function would be proportional to the extent of parenchymal damage. This invites speculation that early, parsimonious use of recruitment maneuvers in severe ARDS, when the lung is more amenable to recruitment and before RV function is irreversibly impaired, paradoxically might reduce RV strain and lessen the likelihood of ACP developing later in the course of ARDS. An alternative or complementary approach is prone positioning, which physicians advocate to enhance the stabilizing effects of PEEP and facilitate lung recruitment.18 Patients with ARDS and ACP placed prone for 18 hours had a significant decrease in Pplat and PaCO2 corresponding with an even more impressive improvement in RV function.11 As local alveolar PO2 primarily determines the magnitude of pulmonary hypoxic vasoconstriction, establishing a PaO2 target for right heart protective ventilation is purely a matter of conjecture. Because the functional residual capacity is essentially the alveolar volume and one of the primary determinants of PaO2 (as well as PVR), measures of pulmonary oxygenation efficiency such as PaO2/FiO2 may be used as a marker for lung recruitment. Therefore, targeting therapies to treat both hypoxemia (PaO2 < 60 mmHg) while increasing PaO2/FiO2 to some arbitrary thresholds (e.g., > 100 or 200 mmHg), may be a reasonable starting point to guide clinical practice until further evidence is forthcoming.
Table 1: Elements of a Right Heart, Lung-Protective Ventilation Strategy |
|
|
Variable / Therapy |
Goal/Impact |
|
Pplat |
≤ 26 cm H2O |
|
Driving pressure (Pplat-PEEP) |
≤ 15 cm H2O |
|
PEEP |
≤ 10 cm H2O* |
|
pH |
At least > 7.20; goal of > 7.30 |
|
PaCO2 |
< 60 mmHg |
|
PaO2 |
≥ 60 mmHg |
|
Prone positiong |
Initiate early (< 72 hours) in severe ARDS with sessions lasting > 16 hours day |
|
Acidosis management: THAM |
Attenuates PAH indirectly by buffering hydrogen ion and binding CO2 Bolus Dosage: THAM (0.3 mol/L) = 0.3 x body weight (kg) x base deficit (mEq/L) Do not exceed 2 mmol/kg /30 min or 5 mmol/kg/h Continuous Infusion Dosage: 0.3-0.6 mmol/kg/hr (not to exceed 15 mmol/kg/day or 3.5 L of 0.3m/L solution See reference 20 for adjustments during renal insufficiency |
|
Inhaled selective pulmonary vasodilator |
Inhaled nitric oxide or aerosolized prostaglandins directly reduce pulmonary vascular resistance through smooth muscle relaxation or indirectly through reduction of hypoxic pulmonary vasoconstriction Inhaled NO: 2-20 ppm Inhaled prostacyclin: 10-50 ng/kg/min |
|
*Although low to moderate PEEP levels are advised, it should be assessed based on whether its application results in more lung recruitment (increased oxygenation and compliance and decreased dead space fraction) or more lung overdistension (decreased compliance and increased dead space fraction) regardless of the impact on oxygenation. |
|
In terms of medications, THAM (trometamol; tris-hydroxymethyl aminomethane), a non-CO2 generating buffer, has been used to reduce PVR and manage acidosis during LPV in ARDS.24 It allows for both correction of acidosis and reduction in PaCO2 without modifying LPV.25 Inhaled vasodilators such as nitric oxide (NO) also cause impressive reductions in PVR during LPV in severe ARDS. In patients with a mean PaCO2 of 65 mmHg, even small doses of inhaled NO (2 ppm) reduced PVR and decreased mean PAP toward levels measured during normocapnia.21 Interestingly, the positive effect of inhaled NO was not related to its impact on gas exchange, as these patients had a PaO2 of approximately 190 mmHg at baseline and PaCO2 was unaffected by NO. Treating acidosis in ARDS with boluses of sodium bicarbonate should be avoided, particularly when dead-space is elevated, as it commonly results in an acute worsening of respiratory acidosis.25
In summary, PAH and ACP are common features of ARDS and require careful reconsideration of LPV and other supportive therapies, such as buffering acidosis, inhaled vasodilators, prone positioning, and perhaps venovenous extracorporeal CO2 removal. In addition, routine echocardiographic evaluation of the effects of these therapies on RV function in patients with severe ARDS appears worthy of serious consideration. In the past 15 years, we have seen tremendous strides in both elucidating the pathophysiology and improving the management of ARDS, resulting in marked reductions in morbidity and mortality. Expanding our focus to consider the role of right heart function to help refine our approach may represent the next step forward.
REFERENCES
- Tomashefski JF, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983;112:112-126.
- Bouferrache K, Vieillard-Baron A. Acute respiratory distress syndrome, mechanical ventilation, and right ventricular function. Curr Opin Crit Care 2011;17:30-35.
- Moloney ED, Evans TW. Pathophysiology and pharmacologic treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J 2003;21:720-727.
- Jardin F, et al. Relationship between transpulmonary pressure and right ventricular isovolumetric pressure change during respiratory support. Cathet Cardiovasc Diagn 1989;16:215-220.
- Bachofen M, Wiebel E. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 1977;116:589-615.
- Namendys-Silva SA, et al. Pulmonary hypertension due to acute respiratory distress syndrome. Braz J Med Biol Res 2014;47:904-910.
- Repesse X, et al. Acute cor pulmonale in ARDS. Rationale for protecting the right ventricle. Chest 2015;147:259-265.
- Vieillard-Baron A, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications and prognosis. Crit Care Med 2001;29:1551-1555.
- Mekantso-Dessap A, et al. Prevalence of and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome. Crit Care Med 2010;38:1786-1792.
- L’heritier G, et al. Prevalence and prognostic value of acute cor pulmonale and patent foramen ovale in ventilated patients with early acute respiratory distress syndrome: A multicenter study. Intensive Care Med 2013;39:1734-1742.
- Vieillard-Baron A, et al. Prone positioning unloads the right ventricle in severe ARDS. Chest 2007;132:1440-1446.
- Greene R, Zapol WM, et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis 1981;124:593-601.
- Monchi M, Bellenfant F, et al. Early predictive factors of survival in the acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;158:1076-1081.
- Squara P, et al. Hemodynamic profile in severe ARDS: Results of the European Collaborative ARDS study. Intensive Care Med 1998;24:1018-1028.
- Jardin F, Viellard-Baron A. Is there a safe plateau pressure in ARDS? The right heart only knows. Intensive Care Med 2007;33:444-447.
- Boissier F, et al. Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome. Intensive Care Med 2013;39:1725-1733.
- Bull TM, et al. NHLBI ARDS Network. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med. 2010;182:1123-1128.
- Viellard-Baron A, et al. Acute cor pulmonale in ARDS. Intensive Care Med 2013;39:1836-1838.
- Amato MBP, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 2015;372:747-755.
- Teplinsky K, et al. Effect of lactic acidosis on canine hemodynamics and left ventricular function. Am J Physiol 1990;258:H1193-H1199.
- Puybasset L, et al. Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiol 1994;80:1254-1267.
- Mekantso-Dessap A, et al. Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med 2009;35:1850-1858.
- Vieillard-Baron A, et al. Increasing respiratory rate to improve CO2 clearance during mechanical ventilation is not a panacea in acute respiratory failure. Crit Care Med 2002;30:1407-1412.
- Nahas GG, et al. Guidelines for the treatment of acidemia with THAM. Drugs 1998;55:191-224.
- Kallet RH, et al. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med. 2000;161:1149-1153.
- Morimont P, et al. Veno-venous extracorporeal CO2 removal improves pulmonary hemodynamics in a porcine ARDS model. Acta Anaesthesiol Scand 2015;59:448-456.
- Schmitt J-M, et al. Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements. Crit Care Med 2001;29:1154-1158.
- Miranda DR, et al. Open lung ventilation does not increase right ventricular impedance: An echo-Doppler study. Crit Care Med 2006;34:2555-2560.
- Naeije R, Brimioulle S. Physiology in medicine: Importance of hypoxic pulmonary vasoconstriction in maintaining arterial oxygenation during acute respiratory failure. Crit Care 2001;5:67-71.
- West JB. Respiratory Physiology: The Essentials. 9th ed. Philadelphia: Wolters Kluwer; 2011:47.
ABSTRACT & COMMENTARY: Right ventricle performance is vulnerable to the effects of both pulmonary disease and positive pressure ventilation.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content
Already have an account? Log in